Trial Profile
An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs GI 6207 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 03 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.
- 03 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.